When Will Covid-19 Vaccinations For Children Under The Age Of 12 Be Available?

When Will Covid-19 Vaccinations For Children Under The Age Of 12 Be Available?

In spite of the fact that adults have been getting COVID-19 vaccinations for eight months, children under the age of 12 are still not eligible for the injections. Many parents are now concerned that their children may get ill – and that they will spread the illness to others in their immediate vicinity.

When Will Covid-19 Vaccinations For Children Under The Age Of 12 Be Available?

Children are susceptible to catching COVID-19 and applying it to others. Fortunately, kids are less likely than adults to suffer from a severe illness. As per the American Academy of Pediatrics, about 4.5 million American children have been infected with COVID-19 since the outbreak began.

When Will Covid-19 Vaccinations For Children Under The Age Of 12 Be Available?

However, the number of severely sick people has been increasing in recent years, with children accounting for a more significant percentage of the total. In the United States, many people are protected by vaccinations, and the highly infectious delta variation is now responsible for the majority of illnesses across the country. According to the American Academy of Pediatrics, about 180,000 children have been infected in the last week. We raise and answer a number of frequently asked issues regarding young children and the COVID-19 vaccination, including the following:

Adults and children aged 12 and older are eligible to get the Pfizer-BioNTech vaccine, known as Comirnaty, manufactured by BioNTech. Moderna and Johnson & Johnson vaccinations are only available to adults due to the fact that their trials in youngsters have not yet been finished. Traditionally, medicines are tested first in adults, then in adolescents, then in children, and finally in smaller children, as long as they are shown to be safe and efficacious in each of the groups studied. A number of major clinical trials using COVID-19 vaccinations, including those involving adults (and, in the case of Pfizer-BioNTech, older teenagers), were conducted in the second part of last year. In contrast, studies involving adolescents and then younger children started early this year.

All three firms are testing their vaccinations on children, starting with teenagers and progressing to 5- to 11-year-olds, then 2- to 5-year-olds, and finally babies and children aged 6 months and older. Babies under the age of one are thought to get some protection from their immunized moms. 

The Centers for Disease Control and Prevention (CDC) advised this week that pregnant women be vaccinated to protect themselves since they are at greater risk for a severe COVID-19 infection. Their unborn child would also benefit from the vaccination. In part because of the fact that the vaccinations have previously been proved safe and efficacious in tens of thousands of people, the studies in children have been scaled down to be on the order of 3,000-4,000 children rather than 30,000-40,000 children. 

Children are less likely than older people to get severely sick due to COVID-19, with the risk of serious illness decreasing with age. As a result, authorities want to ensure that vaccinations are safe enough to be administered to children of different ages.

Advisory committees to the Centers for Disease Control and Prevention and the Food and Drug Administration determined that the advantages of the Pfizer-BioNTech vaccine outweighed the risks for adolescents aged 12 to 15.Pfizer-BioNTech has said that its research in children aged 5 to 11 should be finished by the end of this autumn and that its trial in younger children should be done by the beginning of next year.

Moderna started its clinical studies many months after Pfizer-BioNTech, and it is expected to finish its trials at a later date. Still, the company has not provided a specific completion date. The firm demonstrated in May that their vaccination was both safe and highly efficient in teenagers. According to the findings of the research, none of the 3,700 12- to 17-year-old volunteers who were vaccinated entirely with the active vaccine contracted the virus.